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1015-9584/Copyright ª 2014, Asian SuSummary Background/Objective: Postoperative nauseaand vomiting (PONV) is one of themost
common and distressing adverse events after laparoscopic cholecystectomy (LC). A meta-analysis
of randomized clinical trials (RCTs) was performed to determine the efficacy and safety of dexa-
methasone combined with other antiemetic in the prevention of PONV in patients undergoing LC.
Methods: A systematic literature search was conducted to identify all relevant RCTs. The primary
outcome was PONV in the early period (0e3 hours, 0e4 hours, or 0e6 hours), late period
(>6 hours), and the overall period (0e24 hours).
Results: Nine RCTs with a total of 1089 patients were included in the analysis. Pooled analysis
showed that dexamethasone combined with other antiemetics provided significantly better pro-
phylaxis than single antiemetics in the early period [odds ratio (OR): 0.34; 95% confidence interval
(CI): 0.21e0.55; p < 0.001], late period (OR: 0.35; 95% CI: 0.22e0.57; p < 0.001), and the overall
period (OR: 0.36; 95% CI: 0.27e0.49; p < 0.001). Correspondingly, rescue antiemetic usage was
significantly less in the combination therapy group (OR: 0.22; 95% CI: 0.12e0.41; p < 0.001).
The most frequently reported adverse events were headache, dizziness, and itching. The inci-
dence of adverse events did not differ between the two groups.
Conclusion: Dexamethasone combinedwith other antiemetics was significantly better than single
antiemetics for prophylaxis of PONV in patients undergoing LC, without apparent side effects.
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22 X.-Y. Si et al.1. IntroductionPostoperative nausea and vomiting (PONV) is one of the
most common and distressing adverse events after laparo-
scopic cholecystectomy (LC).1 Dexamethasone, a cortico-
steroid, can effectively prevent PONV.2 To improve
antiemetic efficacy, clinicians often add another agent to
the monotherapy.3 Although there have been several ran-
domized controlled trials (RCTs) evaluating efficacy of the
combination of dexamethasone with other antiemetics for
the prevention of PONV in patients undergoing LC, the
number of patients in the individual trial is often small.4e8
In such settings, the use of a meta-analysis has been
advocated to obtain a more precise estimate of effect
size.9
Therefore, we performed a meta-analysis to evaluate
the available evidence regarding the antiemetic efficacy of
dexamethasone combined with other antiemetics for PONV
compared with single antiemetics in patients undergoing
LC. This study was undertaken following the recommen-
dations of the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) statement.
2. Materials and methods
2.1. Literature search
A computerized search of Medline and Embase databases as
well as the Cochrane Library was performed. The following
MeSH search headings were used: “laparoscopic cholecys-
tectomy”, “dexamethasone”, “nausea”, “vomiting”, “post-
operative”, and “postoperative nausea and vomiting”.
Reference lists in the selected articles were manually
searched for additional studies. The electronic search was
performed from 1 January 1966 to 30 October 2012.
2.2. Inclusion and exclusion criteria
All studies published as full reports of RCTs in the English
language that evaluated the efficacy of prophylactic dexa-
methasone combined with other antiemetics compared
with single antiemetics on PONV in patients undergoing LC
were included. Abstracts, reviews, letters to the editor,
retrospective studies, and animal data were excluded. No
attempts were made to obtain unpublished studies.
2.3. Data extraction
Two reviewers (BL and LW) independently extracted the
following parameters from each study: first author, year
of publication, study population characteristics, study
design, number of patients in each arm, sex, age, inclusion
and exclusion criteria, and outcomes of interest. The inci-
dence of PONV was extracted at three time points: early
period (0e3 hours, 0e4 hours, or 0e6 hours), late period
(>6 h), and overall period (0e24 hours). If the incidence of
events in the overall period was not reported in a study, we
extracted data from the time points with the highest event
rate. Discrepancies between the reviewers were resolved
through discussion until consensus was achieved.2.4. Qualitative analysis
The RCTs were scored using the Jadad scale,10 which
evaluates studies based on randomization (0e2 points),
double-blinding (0e2 points), and withdrawals and drop-
outs (0e1 point). Studies achieving 3 points were
considered to be of higher quality.
2.5. Outcomes of interest
The primary outcome was PONV, which included both
nausea and vomiting.
Secondary outcomes were adverse effects and rescue
antiemetic usage.
2.6. Statistical analysis
Dichotomous variables were summarized using odds ratio
(OR) with a 95% confidence interval (CI). For each compari-
son, heterogeneity was evaluated by c2 and I2. If the statis-
tical test for heterogeneity was present (p < 0.1), a random
effects model was used. If the data were not significantly
heterogeneous (p > 0.1), a fixed effects model was used.
Publication bias was assessed visually using a funnel plot. All
data were analyzed using Review Manager version 5.0
(Cochrane Collaboration, Software Update, Oxford, UK) and
p < 0.05 was considered statistically significant.
3. Results
3.1. Eligible studies
From the electronic databases, we initially identified 10
RCTs that met the eligibility criteria. One study was
excluded because it presented PONV as continuous data,8
so a final total of nine studies published between 2000
and 2012 was included in the present analysis.4e7,11e15 The
study characteristics and patient demographic data are
shown in Tables 1 and 2. Sample size ranged from 80 to 150,
with a total of 1089 patients, of whom 526 received pro-
phylactic dexamethasone plus other antiemetics (combi-
nation therapy group) and 563 received a single antiemetic
(monotherapy group). All of the studies had higher quality.
There were no significant demographic differences be-
tween patients randomized to the combination therapy
group versus the monotherapy group in all the trials.
3.2. Results of meta-analysis
Results of the meta-analysis are presented in Table 3.
Pooled analyses showed that combination therapy provided
significantly better prophylaxis against PONV after LC than
the monotherapy group in the early period (OR: 0.34; 95%
CI: 0.21e0.55; p < 0.001; Fig. 1), late period (OR: 0.35; 95%
CI: 0.22e0.57; p < 0.001; Fig. 2), and overall period (OR:
0.36; 95% CI: 0.27e0.49; p < 0.001; Fig. 3). Correspond-
ingly, rescue antiemetic usage was significantly less in the
combination therapy group (OR: 0.22; 95% CI: 0.12e0.41;
p < 0.001). The most frequently reported adverse events
were headache, dizziness, and itching. The incidence of
adverse events did not differ between the two groups.
Table 1 Characteristics of each trial included in the meta-analysis.
Study Year Country Combination therapy Monotherapy Quality
score
Fujii4 2000 Japan D 8 mg þ G 40 mg/kg IV 15 min prior to induction G 40 mg/kg IV prior to induction 4
Coloma5 2002 USA D 4 mg IV at induction þ Do 12.5 mg IV when the
gallbladder was removed
Do 12.5 mg IV when the gallbladder
was removed
4
Elhakim6 2002 Egypt D 2 mg þ O 4 mg IV prior to induction;
D 4 mg þ O 4 mg IV prior to induction;
D 8 mg þ O 4 mg IV prior to induction;
D 16 mg þ O 4 mg IV prior to induction;
O 4 mg IV prior to induction 5
Biswas7 2003 India D 8 mg þ G 40 mg/kg IV 15 min prior to induction G 40 mg/kg IV prior to induction 5
Nesek-Adam11 2007 Croatia D 8 mg IV after induction of anesthesia þ M 10 mg
IV at the end of surgery
M 10 mg IV at the end of surgery;
D 8 mg after induction
4
Bano12 2008 Ireland D 8 mg þ O 4 mg IV 1 min prior to induction D 8 mg IV 1 min prior to induction 4
Fujii13 2008 D 8 mg þ P 0.5 mg/kg IV at the end of surgery P 0.5 mg/kg IV at the end of surgery 5
Gautam14 2008 Nepal D 8 mg þ O 4 mg IV just prior to induction D 8 mg IV just prior to induction;
O 4 mg IV just prior to induction
5
Jo15 2012 Korea D 8 mg prior to induction þ R 0.3 mg IV 15 min
prior to the end of surgery
D 8 mg IV prior to induction;
R 0.3 mg IV 15 min prior to the end
of surgery
5
D Z dexamethasone; Do Z dolasetron; G Z granisetron; IV Z intravenous M Z metoclopramide; O Z ondansetron, P Z propofol;
R Z ramosetron.
Table 2 Patient characteristics.
Study Group No. of
patients
Age (y) Sex
(male/female)
Weight (kg) Height (cm) Duration of
anesthesia
(min)
Duration
of surgery
(min)
Fujii4 D 8 mg þ G 40 mg/kg 60 47  10 18/42 55  8 156  6 109  32 85  30
G 40 mg/kg 60 47  9 19/41 56  7 158  7 109  37 85  36
Coloma5 D 4 mg þ Do 12.5 mg 70 34  13 16/54 78  20 158  14 112  28 91  27
Do 12.5 mg 70 38  12 14/56 84  25 156  17 117  33 94  27
Elhakim6 D 2 mg þ O 4 mg 30 42 3/22 72  8 160  5 d 106  23
D 4 mg þ O 4 mg 30 41 3/22 70  10 162  6 d 108  32
D 8 mg þ O 4 mg 30 42 4/21 71  9 164  5 d 106  33
D 16 mg þ O 4 mg 30 43 3/22 72  10 160  4 d 100  23
O 4 mg 30 43 4/21 71  9 160  6 d 103  37
Biswas7 D 8 mg þ G 40 mg/kg 60 42.4 10/50 56 d 87  8 74  7
G 40 mg/kg 60 41.3 14/46 54 d 90  6 75  9
Nesek-Adam11 D 8 mg þ M 10 mg 40 50.9  14.5 14/26 68.6  10.9 171.3  12.2 66  16 47  17
D 8 mg 40 49.6  11.7 10/30 70  12.4 170  11.2 65  17 47  18
M 10 mg 40 49.4  13.9 8/32 74.2  14.3 173.3  12.7 67  28 49  25
Bano12 D 8 mg þ O 4 mg 49 41.4  8.2 5/44 68.9  5.6 d 88.0  5.9 61.9  8.1
D 8 mg 48 39.3  8.6 7/41 69.02  6.3 d 88.2  5.5 62.9  7.8
Fujii13 D 8 mg þ P 0.5 mg/kg 40 48  11 17/23 55  7 158  8 84  32 107  34
P 0.5 mg/kg 40 47  9 16/24 57  9 160  8 89  30 113  32
Gautam14 D 8 mg þ O 4 mg 47 38.8  11.2 4/43 56.6  6.7 152  5 90.1  20.7 72.8  18.6
D 8 mg 47 39.2  8.5 5/42 61.2  5.7 150  6 97.9  21.1 79.7  19
O 4 mg 48 38.2  9.2 4/44 59.9  7.1 150  6 95.5  20.6 77.6  19
Jo15 D 8 mg þ R 0.3 mg 40 44  10 0/40 58  8 158  5 71  15 50  15
D 8 mg 40 44  12 0/40 60  9 159  5 69  27 43  15
R 0.3 mg 40 48  13 0/40 58  9 158  5 67  14 44  10
D Z dexamethasone; Do Z dolasetron; G Z granisetron; M Z metoclopramide; O Z ondansetron; P Z propofol; R Z ramosetron.
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Table 3 Results of a meta-analysis.
Outcome of interest No. of studies No. of patients Results, % OR 95% CI p I2 (%)
Early period PONV 6 (4,6,7,11,14,15) CT Z 367, MT Z 405 CT Z 9.8, MT Z 24.9 0.34 0.21e0.55 <0.001 0
Late period PONV 4 (6,11,14,15) CT Z 247, MT Z 285 CT Z 21, MT Z 31.2 0.35 0.22e0.57 <0.001 0
Overall period PONV 9 (4e7,11e15) CT Z 526, MT Z 563 CT Z 22, MT Z 38.9 0.36 0.27e0.49 <0.001 0
Rescue 6 (4,6,7,11,12,14) CT Z 376, MT Z 373 CT Z 4.2, MT Z 15.8 0.22 0.12e0.41 <0.001 0
Adverse events
Headache 6 (4,6,7,11,14,15) CT Z 367, MT Z 405 CT Z 7.9, MT Z 6.4 1.17 0.66e2.08 0.58 0
Dizziness 6 (4,6,7,11,14,15) CT Z 367, MT Z 405 CT Z 3.8, MT Z 3.7 1.12 0.53e2.38 0.76 0
Itching 3 (6,12,14) CT Z 216, MT Z 173 CT Z 3.2, MT Z 4.0 0.94 0.26e3.38 0.92 0
CI Z confidence interval; CT Z combination therapy; MT Z monotherapy; OR Z odds ratio; PONV Z postoperative nausea and
vomiting.
24 X.-Y. Si et al.3.3. Subgroup analysis
Results of the subgroup analysis are shown in Table 4.
3.3.1. Dexamethasone dose
One study compared four doses of dexamethasone (2 mg,
4 mg, 8 mg, and 16 mg) and found that 8 mg represented
the optimal effective dose in combination with ondansetron
to prevent PONV after LC.6
3.3.2. Combination therapy versus dexamethasone alone
Dexamethasone 8 mg plus ondansetron 4 mg or metoclo-
pramide 10 mg or ramosetron 0.3 mg was compared with
dexamethasone 8 mg alone in four trials.11,12,14,15 Analysis
of these studies revealed a significantly reduced incidence
of PONV and less rescue antiemetic usage in the combina-
tion therapy group.
3.3.3. Dexamethasone plus ondansetron versus
ondansetron alone
Dexamethasone 8 mg plus ondansetron 4 mg was compared
with ondansetron 4 mg alone in two trials.6,14 As Table 4
shows, our results indicate that PONV incidence and
rescue antiemetic usage were significantly lower in the
dexamethasone plus ondansetron group.
3.3.4. Dexamethasone plus granisetron versus
granisetron alone
Pooled analyses of two trials showed that dexamethasone
8 mg plus granisetron 40 mg/kg provided significantly betterFigure 1 Forest plot displaying the results of the meta-analysprophylaxis against PONV than granisetron 40 mg/kg
alone.4,7
3.3.5. Dexamethasone plus dolasetron versus dolasetron
alone
Dexamethasone 4 mg plus dolasetron 12.5 mg was
compared with dolasetron 12.5 mg alone in one trial.5
Although the incidences of nausea (35%) and vomiting
(8%) were lower in the combination group, this difference
did not achieve statistical significance (p Z 0.1 and
p Z 0.3, respectively).
3.3.6. Dexamethasone plus ramosetron versus
ramosetron alone
In one study, the antiemetic efficacy of the combination of
ramosetron 0.3 mg and dexamethasone 8 mg was found to
be superior to that of ramosetron 0.3 mg alone (p < 0.05).15
3.3.7. Dexamethasone plus metoclopramide versus
metoclopramide alone
Dexamethasone 8 mg plus metoclopramide 10 mg was
compared with metoclopramide 10 mg alone in one trial.11
The authors found that patients receiving combination
therapy had significantly less PONV than those administered
10 mg metoclopramide alone during 24 hours (p Z 0.033).
3.3.8. Dexamethasone plus propofol versus propofol
alone
In one study, dexamethasone 8 mg combined with propofol
0.5 mg/kg was found to be superior to propofol 0.5 mg/kg
alone for prevention of PONV in patients undergoing LCis of postoperative nausea and vomiting in the early period.
Figure 2 Forest plot displaying the results of the meta-analysis of postoperative nausea and vomiting in the late period.
Dexamethasone in laparoscopic cholecystectomy 25(p Z 0.029).13 No heterogeneity was detected for any
outcome assessed.
3.4. Publication bias
A funnel plot of the studies used in the meta-analysis
reporting on PONV in the overall period is shown in Fig. 4.
None of the studies lay outside the limits of the 95% CI,
indicating no evidence of publication bias.
4. Discussion
Since its first introduction in 1985, LC has been widely
accepted as the standard procedure for gallbladder
removal.16 Compared to the open approach,17 the advan-
tages of this procedure included less pain, quicker recov-
ery, shorter hospital stay, and a better cosmetic result.1
However, during the first 24 hours after surgery, 50e70%
of LC patients experience PONV,1 which is associated with
an increased risk of bleeding, wound dehiscence, aspiration
of gastric contents, fluid and electrolyte imbalance, dehy-
dration, delayed hospital discharge, unexpected hospital
admission, and decreased satisfaction in surgical pa-
tients.18 Several risk factors for PONV have been reported,
including female sex, nonsmoking status, a history of mo-
tion sickness or previous PONV, and use of postoperative
opioids.1
Physiologically, the vomiting reflex is a complex act
mediated by the emetic center located in the medulla
oblongata. This center receives emetic stimuli from the
periphery via afferent neurons of the vagus nerves. Emetic
stimuli also come centrally from chemoreceptive trigger
zones, vestibular apparatus, solitary tract nucleus,Figure 3 Forest plot displaying the results of the meta-analysiscerebellum, and higher cerebral cortex. These structures
are rich in nausea and vomiting related functional receptors
(serotonin type 3, dopamine type 2, muscarinic cholinergic
type 1, histamine type 1, and opioid).19 There is no single
stimulus or cause for PONV, thus, a combination of anti-
emetics may be more effective than a single antiemetic.
This meta-analysis suggests that dexamethasone com-
bined with other antiemetics provide better prophylaxis
against PONV than a single antiemetic drug after LC. The
possible mechanisms for increased antiemetic effect are as
follows: (1) corticosteroidsmayaffects 5-hydroxytryptamine
(5-HT) turnover in the in neural tissue by shunting the
metabolism of tryptophan away from 5-HT pathways; (2)
corticosteroids may prevent the release of 5-HT in the gut or
prevent activation of 5-HT receptors in the gastrointestinal
system; and (3) dexamethasone may potentiate the main
effect of other antiemetics by sensitizing the pharmacolog-
ical receptor.20,21
As far as the complication rate is concerned, no trials
presented any statistically significant difference among the
study groups. The pooled result is also in line with these
trials. No corticosteroid-related adverse effects, such as
increased risk of infection, delayed wound healing, glucose
intolerance, and adrenal suppression, were noted in the
combination therapy group. The safety and effectiveness of
such prophylaxis was confirmed in this analysis.
Seven RCTs have been undertaken to investigate the
antiemetic efficacy of the combination of dexamethasone
and 5-HT3 antagonists (ondansetron, granisetron, dolase-
tron, and ramosetron). Only one trial failed to find that the
combination was superior to the single antiemetic drug in
reducing the incidence of PONV.5 These results could have
been biased by the inefficient dose of dexamethasone
(4 mg) used. Currently, the recommended dose ofof postoperative nausea and vomiting in the overall period.
Table 4 Results of a subgroup analysis.
Outcome of interest No. of studies No. of patients Results, % OR 95% CI p I2 (%)
CT versus dexamethasone alone
Early period PONV 3 (11,14,15) CT Z 127, MT Z 127 CT Z 16.5, MT Z 33.8 0.30 0.15e0.60 <0.001 26
Late period PONV 4 (6,11,14,15) CT Z 247, MT Z 285 CT Z 21.0, MT Z 31.2 0.35 0.22e0.57 <0.001 0
Overall period PONV 4 (11,12,14,15) CT Z 176, MT Z 175 CT Z 21.5, MT Z 40.5 0.36 0.22e0.60 <0.001 0
Rescue 3 (11,12,14) CT Z 136, MT Z 135 CT Z 5.1, MT Z 20 0.21 0.09e0.51 <0.001 0
Adverse events
Headache 3 (11,14,15) CT Z 127, MT Z 127 CT Z 7.8, MT Z 4.7 1.72 0.61e4.90 0.31 0
Dizziness 3 (11,14,15) CT Z 127, MT Z 127 CT Z 3.1, MT Z 3.9 0.81 0.23e2.90 0.75 0
Itching 2 (12,14) CT Z 96, MT Z 95 CT Z 2.0, MT Z 2.1 0.99 0.17e5.83 0.99 0
Dexamethasone plus ondansetron versus ondansetron alone
Early period PONV 2 (6,14) CT Z 77, MT Z 78 CT Z 16.5, MT Z 33.8 0.20 0.04e0.96 0.04 0
Late period PONV 2 (6,14) CT Z 77, MT Z 78 CT Z 9.0, MT Z 29.4 0.21 0.08e0.55 <0.001 0
Overall period PONV 2 (6,14) CT Z 77, MT Z 78 CT Z 12.9, MT Z 39.4 0.22 0.10e0.50 <0.001 0
Rescue 2 (6,14) CT Z 77, MT Z 78 CT Z 5.1, MT Z 24.3 0.18 0.06e0.54 0.002 0
Adverse events
Headache 2 (6,14) CT Z 77, MT Z 78 CT Z 7.7, MT Z 7.6 1.01 0.31e3.29 0.98 0
Dizziness 2 (6,14) CT Z 77, MT Z 78 CT Z 2.5, MT Z 2.5 1.01 0.17e6.00 0.99 0
Itching 2 (6,14) CT Z 77, MT Z 78 CT Z 2.5, MT Z 2.5 1.01 0.17e6.00 0.99 0
Dexamethasone plus granisetron versus granisetron alone
Early period PONV 2 (4,7) CT Z 120, MT Z 120 CT Z 4.1, MT Z 15.8 0.23 0.08e0.64 0.005 0
Overall period PONV 2 (4,7) CT Z 120, MT Z 120 CT Z 4.1, MT Z 18.3 0.19 0.07e0.53 0.001 0
Rescue 2 (4,7) CT Z 120, MT Z 120 CT Z 0.8, MT Z 7.5 0.15 0.03e0.84 0.03 0
Adverse events
Headache 2 (4,7) CT Z 120, MT Z 120 CT Z 9.1, MT Z 9.1 1.00 0.42e2.40 1.00 0
Dizziness 2 (4,7) CT Z 120, MT Z 120 CT Z 6.6, MT Z 5.8 1.15 0.40e2.29 0.79 0
CI Z confidence interval; CT Z combination therapy; MT Z monotherapy; OR Z odds ratio; PONV Z postoperative nausea and
vomiting.
26 X.-Y. Si et al.dexamethasone in the prevention of PONV is 8e10 mg.
Dexamethasone has been proven to be a less efficacious
antiemetic agent at a dose of 4 mg.6
Metoclopramide acts on central dopaminergic receptors,
on both central and peripheral 5-HT3 receptors and on
peripheral 5-HT4 receptors. It is a prokinetic drug that in-
creases gastric and small intestinal motility.22 One of the
trials included in the current analysis showed that patients
who received dexamethasone 8 mg after the induction ofFigure 4 Funnel plot demonstrating symmetry for post-
operative nausea and vomiting in the overall period, indicating
no evidence of publication bias.anesthesia and metoclopramide 10 mg at the end of LC had
significantly less PONV than those administered 10 mg
metoclopramide along or saline placebo.11 By contrast,
Maddali et al23 demonstrated that combination of dexa-
methasone 8 mg and metoclopramide 10 mg prior to in-
duction of general anaesthesia does not appear to be an
effective antiemetic in diagnostic gynecological laparo-
scopic procedures. This difference must have been attrib-
utable to timing of the metoclopramide administration.
Metoclopramide is a short-lasting drug, which has a serum
half-life of 2.5e6 hours. Therefore, its prophylactic anti-
emetic effect at the start of surgery may have worn off by
the time the patient is fully awake.24
Propofol has an antiemetic effect even though the exact
mechanism of action is still unclear. Possible explanations
include blocking the 5-HT3 receptor of the serotonergic
system, and inhibition of the chemoreceptor trigger zone
and vagal nuclei.25 In one study, dexamethasone 8 mg
combined with propofol 0.5 mg/kg was found to be superior
to propofol 0.5 mg/kg alone for prevention of PONV in pa-
tients undergoing LC (p Z 0.029).13
Our study had some limitations. Although combination of
dexamethasone and 5-HT3 antagonists is likely to be the
most commonly used combination regimen, the high cost of
5-HT3 antagonists remains a major concern in current health
care systems. By contrast, metoclopramide and propofol
are inexpensive drugs. Further investigation is therefore
required to provide an accurate cost-effectiveness com-
parison between different combination regimens. Another
Dexamethasone in laparoscopic cholecystectomy 27limitation was that studies published in languages other than
English were not included in the review, which may have
introduced publication bias. However, there was evidence
that language restriction of a meta-analysis other than En-
glish did not lead to bias estimates of intervention
effectiveness.26
In conclusion, this meta-analysis showed the benefits of
dexamethasone combined with other antiemetics in the
prophylaxis of PONV in patients undergoing LC. All the
studies included in this analysis were randomized double-
blind design with higher quality. Additionally, there was no
evidence of heterogeneity between studies (I2 Z 0%) or
publication bias. We therefore believe that the results are
reliable. It is evident that the use of prophylactic anti-
emetic therapy in patients at high risk was more effective
in preventing PONV and achieved greater patient satisfac-
tion at a lower cost compared with placebo.27 Combination
prophylaxis should be considered particularly for patients
with high risk factors.
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